Factors affecting the progression of renal disease in autosomal-dominant polycystic kidney disease

Autosomal-dominant polycystic kidney disease results in renal failure at a varying age from childhood to old age. We postulated that factors other than the culprit gene alone contribute to the course of progression of the renal failure. We studied 580 subjects with autosomal-dominant polycystic kidney disease and 194 unaffected family members. We calculated survival curves to end-stage renal failure or death and developed a linear model for testing the effects of single or multiple variables on the progression of renal failure as estimated from the reciprocal of serum creatinine. Fifty-two subjects died and 94 reached end-stage renal failure during the period of observation, yielding functional survivals of 71% at age 50 years, 53% at 58 years and 23% at 70 years. The following variables were independently associated with worse mean renal function at a given age (P value less than 0.01): the PKD1 gene, younger age at diagnosis, male gender, hypertension, increased left ventricular mass, hepatic cysts in women, three or more pregnancies, gross hematuria, urinary tract infections in men and renal size expressed as renal volume. The following were not associated significantly with the course of renal function: gender of affected parent, mitral valve prolapse, intracranial aneurysms, any pregnancy, hepatic cysts in men and urinary tract infections in women. The identification of unalterable maleficent factors such as the PKD1 gene and male gender permit more informed counseling while the identification of alterable factors such as hypertension, number of pregnancies and recurrent urinary tract infections provides the clinician with the opportunity to modify these factors and improve the management of patients with autosomal-dominant polycystic kidney disease.

[1]  C. Patrono,et al.  Evidence for a renal origin of urinary thromboxane B2 in health and disease. , 1983, Advances in prostaglandin, thromboxane, and leukotriene research.

[2]  S. Yokoyama,et al.  Specific sorbent of apolipoprotein B-containing lipoproteins for plasmapheresis. Characterization and experimental use in hypercholesterolemic rabbits. , 1984, Arteriosclerosis.

[3]  H. Mabuchi,et al.  A new low density lipoprotein apheresis system using two dextran sulfate cellulose columns in an automated column regenerating unit (LDL continuous apheresis). , 1987, Atherosclerosis.

[4]  M. Karnovsky,et al.  Exacerbation of chronic aminonucleoside nephrosis by dietary cholesterol supplementation. , 1987, Kidney international.

[5]  T. Miyahara,et al.  Possible therapeutic application of low density lipoprotein apheresis (LDL-A) in conjunction with double filtration plasmapheresis (DFPP) in drug-resistant nephrotic syndrome due to focal glomerular sclerosis (FGS). , 1988, Nihon Jinzo Gakkai shi.

[6]  S. Klahr,et al.  Lovastatin ameliorates the development of glomerulosclerosis and uremia in experimental nephrotic syndrome. , 1990, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[7]  G. Remuzzi,et al.  Preliminary report: renal thromboxane A2 synthesis in children with frequent relapsing nephrotic syndrome , 1990, The Lancet.

[8]  R. Hené,et al.  Partial remission of nephrotic syndrome in patient on long-term simvastatin , 1990, The Lancet.

[9]  B. Kasiske,et al.  Hyperlipidemia and progressive renal disease. , 1991, Kidney international. Supplement.

[10]  J. Moorhead Lipids and progressive kidney disease. , 1991, Kidney international. Supplement.